Answers are grounded in this paper and cite their sources.
Narrative review evaluates iron chelation outcomes in transfusion-dependent β-thalassemia, highlighting implications for practice.
INTRODUCTION: Transfusion-dependent β-thalassemia (TDT) has become a chronic, survivable condition, but transfusional iron overload remains a central driver of cardiac, hepatic, and endocrine morbidity. Clinicians increasingly encounter patients whose iron indices 'stall' despite seemingly appropriate chelation, creating uncertainty about whether the problem is correctable (iron balance, adherence, dosing) or reflects a harder biological limitation in iron mobilization. AREAS COVERED: A narrative review of pivotal randomized trials, prospective cohorts, and major observational MRI datasets evaluating deferoxamine, deferiprone, deferasirox, and combination regimens in TDT was performed. Literature was identified via structured searches of PubMed and key hematology/cardiometabolic journals (2000-February 2026), prioritizing primary studies with MRI liver iron concentration (LIC) and cardiac T2* endpoints, and supplemented by regulatory prescribing information for safety monitoring. EXPERT OPINION/COMMENTARY: 'biological ceiling,' may arise when stored iron becomes less accessible (slow-turnover pools, tissue remodeling, altered export). Clinicians can disentangle these mechanisms by integrating transfusion iron input calculations with serial multi-organ MRI trajectories, then tailoring chelator strategy to the dominant iron compartment and organ risk.
No takes yet. Share an insight, caveat, or question.
Delicou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: